fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approves Kerendia in chronic kidney disease (CKD) associated with type 2 diabetes – Bayer HealthCare

Written by | 21 Jul 2021

Bayer announced the FDA has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death,… read more.

EMA gives green light for 8 new medicines

Written by | 17 Jul 2021

The European Medicine Agency’s key decision-making committee on human medicines (CHMP), has recommended eight medicines for approval at its June meeting.  The Committee recommended granting a conditional marketing authorisation for Abecma… read more.

Diurnal receives marketing authorisation for Efmody to treat congenital adrenal hyperplasia from the MHRA (UK)

Written by | 15 Jul 2021

Diurnal Group plc announces that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorisation for Efmody (hydrocortisone modified-release hard capsules – development name… read more.

Advicenne receives MHRA approval to market Sibnayal in the UK for the treatment of distal renal tubular acidosis

Written by | 14 Jul 2021

Advicenne announces that the Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Sibnayal (ADV 7103) in the UK, for the treatment of distal renal… read more.

Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation

Written by | 13 Jul 2021

Hansa Biopharma, announced three-year follow-up data in crossmatch positive patients who received imlifidase prior to kidney transplantation. As reported in an article, which has been accepted for publication… read more.

Forxiga recommended for approval in the EU by CHMP for the treatment of patients with chronic kidney disease – AstraZeneca

Written by | 7 Jul 2021

AstraZeneca’s Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes… read more.

Tizepatide shows efficacy and safety in diabetes treatment

Written by | 5 Jul 2021

Article by Bruce Sylvester. Investigative tirzepatide appears to improve glycaemic control and bodyweight in Type 2 diabetes patients, without raising the risk of hypoglycemia. Researchers reported these findings… read more.

Jardiance is EU approved for the treatment of heart failure with reduced ejection fraction – Boehringer + Eli Lilly

Written by | 30 Jun 2021

The European Commission has granted marketing authorization for Jardiance (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer… read more.

ASCO 2021: Pembrolizumab shows promise for adjuvant treatment of renal cell carcinoma

Written by | 18 Jun 2021

Immunotherapy with pembrolizumab after surgery significantly improves disease-free survival among patients with the most prevalent form of  kidney cancer, clear-cell renal carcinoma. Researchers reported this finding on June… read more.

Home isolation and ivermectin-based treatment kits

Written by | 21 May 2021

Interview and article by Christine Clark. Dr Suryakant (Head of the Department of Respiratory Medicine at King George Medical University in Lucknow, India) explains how an ivermectin-based therapy… read more.

Researchers find enzyme that could unlock kidney treatment

Written by | 15 May 2021

Article written by Gary Finnegan. Chronic kidney disease affects approximately 700 million people worldwide with many going on to require dialysis. Now a new enzyme has been discovered… read more.

European Commission approves Benlysta for adult patients with active lupus nephritis – GSK

Written by | 13 May 2021

GlaxoSmithKline plc announced the European Commission has approved the expanded use of intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.